Halozyme completed the acquisition of Elektrofi for $900m.

Halozyme, a biopharmaceutical company, completed the acquisition of Elektrofi, a biopharmaceutical company, for $900m. "Completing the acquisition of Elektrofi is a strategic milestone in our mission to expand Halozyme's drug delivery technology offerings to biopharma companies. With the addition of the Hypercon ultra-high concentration microparticle formulation technology, we will be able to offer partners a diverse portfolio of drug delivery solutions. The acquisition adds an additional high growth potential, royalty revenue business that is complementary to the strong ENHANZE royalty business to drive long-term royalty growth for decades to come," Dr. Helen Torley, Halozyme President and Chief Executive.